US FDA Classifies Aurobindo Pharma's Lannett Facility as Official Action Indicated
Aurobindo Pharma Ltd · Others (Uncategorized) · 12 Nov 2026, 2:04 am
US FDA Classifies Aurobindo Pharma's Lannett Facility as Official Action Indicated The US FDA has classified the inspection of Lannett Company LLC—a wholly owned step-down subsidiary of Aurobindo Pharma located in Seymour, Indiana—as "Official Action Indicated" (OAI). The facility was inspected between 17th Aug'26 and 21st Aug'26, resulting in four observations to which the company previously responded. Aurobindo Pharma received the OAI communication on 11th Nov'26. The company stated that this classification has no quantifiable monetary or operational impact on its financials or business activities.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Submission of Earning Call Transcript for Q2FY27. · 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". · 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. · 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. · 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. · 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. · 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. · 05 Nov 2026
- Approved the proposal of Merger of two wholly owned subsidiaries of the Company. · 05 Nov 2026
